Nestlé Health Science Subsidiary will Invest $65 Million in Biotech Start-Up

Nestlé Health Science Subsidiary will Invest $65 Million in Biotech Start-Up

Photo Sasabune Omakase Modified: Flickr/erin/CC 4.0

Nestlé Health Science is exploring ways to advance methods of nutritional therapy over traditional drugs.

Nestlé Health Science, the four year-old subsidiary of Nestlé which specializes in nutritional therapy, has invested $65 million in Seres Heath, a start-up that focuses on “restoring the microbiome” that is responsible for vital human functions, according to DealBook.

Nestlé’s investment in Seres Health marks a conscious effort from the company to widen its role in nutritional therapy as it relates to healthcare. Nestlé Health Science has reportedly also partnered with Flagship Ventures, a venture capital firm which helps “incubate start-ups in the nutritional therapy field.”

Earlier in 2014, it was scientists at the Nestlé Institute of Health Sciences who were in the process of developing food products that help exercise your muscles for you.

In a telephone interview with Dealbook, Greg Behar, Nestlé Health Science’s chief executive, indicated that the partnership was one of many acquisitions to come that would help the company bridge the gap between nutrition and healthcare.

“There are some specific diseases where we know nutrition plays a very important role,” said Behar. “This therapeutic approach to nutrition offers great growth opportunities in the next three to five years.”

Rate this Story